18 and older, any sex, with Metastatic Melanoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Clinical ResponsePrimary· 12 weeks, or until development of new metastases or recurrence
At the end of 12 week follow up, the proportion of patients that showed clinical response (CR) determined by the disappearance of all target lesions, or partial response (PR) will be calculated. The patient is determined to have partial response as if 30% reduction in the sum of the longest diameter (SLD) of target lesions are shown from the baseline sum LD.
Group
Value
95% CI
Tumor Infiltrating Lymphocytes (TIL)
0
Tumor Infiltrating Lymphocytes (TIL)
0
Tumor Infiltrating Lymphocytes (TIL)
1
Adverse events — posted to ClinicalTrials.gov
Time frame: Single patient treated, data collected from baseline up to 72 days..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this protocol is to determine whether autologous TIL infused in conjunction with systemic high-dose IL-2 after non-myeloablative chemotherapy with cyclophosphamide and fludarabine can cause consistent and durable objective responses in patients who have metastatic melanoma at the John Wayne Cancer Institute (JWCI).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
Other trials of Tumor Infiltrating Lymphocytes (TIL)
Trials testing the same drug.
NCT06640582 — TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
· Phase 1, PHASE2
· recruiting
NCT06530303 — Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
· Phase 1, PHASE2
· recruiting
NCT06532799 — TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
· Phase 1, PHASE2
· recruiting
NCT06532812 — TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
· Phase 1, PHASE2
· recruiting
NCT06538012 — TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
· Phase 1, PHASE2
· recruiting
Other recruiting trials for Metastatic Melanoma
Currently open trials in the same condition.
NCT06066138 — A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
· Phase 1
· recruiting
NCT07237100 — Mirdametinib in Patients With Advanced NF1-mutant Melanoma
· Phase 2
· recruiting
NCT07086105 — A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma
· Phase 1
· recruiting
NCT07112170 — Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma
· NA
· recruiting
NCT06488365 — In Vivo Liquid Biopsy of Melanoma (Cytophone)
· NA
· recruiting
Other Saint John's Cancer Institute trials
Trials by the same sponsor.
NCT05289466 — Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With P
· NA
· terminated
NCT03955042 — Pemetrexed for the Treatment of Chordoma
· Phase 1
· completed
NCT04082611 — The PREVENTION Trial: Precision Recommendations to Optimize Neurocognition
· NA
· completed
NCT04603209 — Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer
· recruiting
NCT03069287 — Integrating Family Caregiver Support Into Cancer Clinical Trials
· NA
· withdrawn
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Saint John's Cancer Institute
Last refreshed: 22 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02375984.